<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Allegretti M</submitter><funding>Ministero della Salute</funding><funding>Fondazione AIRC per la ricerca sul cancro ETS</funding><pagination>26</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12853808</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>45(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Cancer resistance is one of the major challenges in oncology, often resulting in disease relapse and poor patient outcomes. Within the RNA family, microRNAs (miRNAs) regulate core biological processes and have been recognized also as critical contributors of tumor resistance and therapy failure. Being pivotal, they are increasingly exploited as biomarkers in various settings. Although in silico analyses facilitate miRNAs identification, PCR-based approaches remain essential to validate their expression. Currently, a plethora of well-established, single-target methods exist but multiplex detection from the same input have been only rarely explored.&lt;h4>Methods&lt;/h4>We present miRquad, the first-in-class digital PCR (dPCR) TaqMan™ multiplex clinical research assay for miRNA </pubmed_abstract><journal>Journal of experimental &amp; clinical cancer research : CR</journal><pubmed_title>miRquad: first-in-class dPCR multiplex TaqMan™ Advanced clinical research assay for microRNA detection in head and neck cancer.</pubmed_title><pmcid>PMC12853808</pmcid><funding_grant_id>IG 29040</funding_grant_id><funding_grant_id>PNC E3-2022-23683266</funding_grant_id><pubmed_authors>Stevens JF</pubmed_authors><pubmed_authors>Pellini R</pubmed_authors><pubmed_authors>Moccia T</pubmed_authors><pubmed_authors>Urbani G</pubmed_authors><pubmed_authors>Maestro R</pubmed_authors><pubmed_authors>De Summa S</pubmed_authors><pubmed_authors>Pisani A</pubmed_authors><pubmed_authors>Azzariti A</pubmed_authors><pubmed_authors>Ganci F</pubmed_authors><pubmed_authors>Arbustini E</pubmed_authors><pubmed_authors>Urtis M</pubmed_authors><pubmed_authors>Di Gennaro E</pubmed_authors><pubmed_authors>Sigalotti L</pubmed_authors><pubmed_authors>Gagliardi S</pubmed_authors><pubmed_authors>Allegretti M</pubmed_authors><pubmed_authors>De Pascale V</pubmed_authors><pubmed_authors>Ciliberto G</pubmed_authors><pubmed_authors>Fiori S</pubmed_authors><pubmed_authors>Blandino G</pubmed_authors><pubmed_authors>Muti PCM</pubmed_authors><pubmed_authors>Joun DJ</pubmed_authors><pubmed_authors>Ciardiello C</pubmed_authors><pubmed_authors>Budillon A</pubmed_authors><pubmed_authors>Ferrero S</pubmed_authors><pubmed_authors>Beltramini GA</pubmed_authors></additional><is_claimable>false</is_claimable><name>miRquad: first-in-class dPCR multiplex TaqMan™ Advanced clinical research assay for microRNA detection in head and neck cancer.</name><description>&lt;h4>Background&lt;/h4>Cancer resistance is one of the major challenges in oncology, often resulting in disease relapse and poor patient outcomes. Within the RNA family, microRNAs (miRNAs) regulate core biological processes and have been recognized also as critical contributors of tumor resistance and therapy failure. Being pivotal, they are increasingly exploited as biomarkers in various settings. Although in silico analyses facilitate miRNAs identification, PCR-based approaches remain essential to validate their expression. Currently, a plethora of well-established, single-target methods exist but multiplex detection from the same input have been only rarely explored.&lt;h4>Methods&lt;/h4>We present miRquad, the first-in-class digital PCR (dPCR) TaqMan™ multiplex clinical research assay for miRNA </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-17T03:22:49.283Z</modification><creation>2026-06-17T03:10:43.878Z</creation></dates><accession>S-EPMC12853808</accession><cross_references><pubmed>41422030</pubmed><doi>10.1186/s13046-025-03590-6</doi></cross_references></HashMap>